FDA Warns CVS Health, Walgreens, and Others About Marketing Unapproved Eye Products

1 Mins read

The U.S. Food and Drug Administration (FDA) has issued a warning to CVS Health Corp. and Walgreens Boots Alliance Inc., along with several smaller consumer products companies, regarding the marketing of unapproved eye products. This announcement comes amidst concerns that these unlawfully marketed ophthalmic drugs pose an elevated risk of harm to users due to the bypassing of natural ocular defenses.

Heightened Risk of Harm

In a press release issued on Tuesday, the FDA expressed particular concern over the potential dangers associated with these unapproved eye products. The application of drugs to the eyes negates certain protective mechanisms in the body, amplifying the risk posed to users. Consequently, the FDA has taken action to address this issue.

Unapproved New Drugs

In a letter addressed to Walgreens on Monday, the FDA highlighted several eye-drop products available on the company’s website that are considered unapproved new drugs. The delivery of these products across state boundaries may be in violation of federal law. Similarly, a letter was also sent to CVS, cautioning against the sale of “CVS Health Pink Eye Relief Drops” on their website.

Manufacturing Concerns

The FDA not only expressed apprehension regarding the marketing of these unapproved eye products but also raised concerns about the manufacturing practices employed by the contract manufacturers responsible for producing them. Such concerns further reinforce the urgency for corrective actions.

Taking Action

The FDA has given CVS and Walgreens, along with the other implicated companies, 15 working days to inform the agency of the measures they have taken to rectify the violations. However, CVS and Walgreens have yet to respond to requests for comment.

As a result of this announcement, CVS shares experienced a 0.7% increase on Tuesday, while Walgreens stock saw a 0.6% gain.

These warnings issued by the FDA emphasize the importance of adhering to regulations and ensuring that all eye products undergo the necessary approval processes. By doing so, the safety and well-being of consumers can be adequately protected.

Related posts

Anglo American 2023 Financial Overview

2 Mins read
Revenue Forecast The diversified mining major is expected to post a full-year revenue of $30.83 billion, a decline from the prior-year’s figure…

National Australia Bank First-Quarter Profit Decline

1 Mins read
In its recent update, National Australia Bank (NAB) announced a decline in profit for the fiscal first quarter compared to the previous…

Mondelez Resilience in Tough Times

2 Mins read
As the dust settles on a challenging earnings season for consumer staples companies, Mondelez strides ahead. Despite inflation-driven price hikes squeezing consumer…

Leave a Reply

Your email address will not be published. Required fields are marked *